A detailed history of National Bank Of Canada transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, National Bank Of Canada holds 613 shares of ALNY stock, worth $150,454. This represents 0.0% of its overall portfolio holdings.

Number of Shares
613
Previous 613 -0.0%
Holding current value
$150,454
Previous $168,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$233.81 - $287.01 $3,039 - $3,731
-13 Reduced 2.08%
613 $168,000
Q2 2024

Aug 02, 2024

SELL
$143.31 - $247.0 $15.4 Million - $26.6 Million
-107,784 Reduced 99.42%
626 $152,000
Q1 2024

May 13, 2024

BUY
$146.51 - $198.2 $15.8 Million - $21.4 Million
107,897 Added 21032.55%
108,410 $16.2 Million
Q4 2023

Feb 06, 2024

BUY
$151.41 - $196.57 $4,239 - $5,503
28 Added 5.77%
513 $98,000
Q3 2023

Oct 10, 2023

SELL
$170.77 - $211.65 $474,911 - $588,598
-2,781 Reduced 85.15%
485 $85,000
Q2 2023

Jul 26, 2023

BUY
$185.01 - $212.05 $26,456 - $30,323
143 Added 4.58%
3,266 $620,000
Q1 2023

Apr 12, 2023

SELL
$182.66 - $235.53 $202,569 - $261,202
-1,109 Reduced 26.21%
3,123 $625,000
Q4 2022

Jan 24, 2023

SELL
$185.53 - $241.31 $436,181 - $567,319
-2,351 Reduced 35.71%
4,232 $0
Q3 2022

Oct 13, 2022

SELL
$138.54 - $232.0 $778,179 - $1.3 Million
-5,617 Reduced 46.04%
6,583 $1.3 Million
Q2 2022

Jul 28, 2022

BUY
$120.42 - $169.29 $1,324 - $1,862
11 Added 0.09%
12,200 $1.81 Million
Q1 2022

May 05, 2022

BUY
$127.18 - $173.91 $938,842 - $1.28 Million
7,382 Added 153.57%
12,189 $2.05 Million
Q4 2021

Jan 24, 2022

BUY
$159.56 - $209.29 $767,004 - $1.01 Million
4,807 New
4,807 $796,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.